Immunoregulatory Proteases in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease leading to in ammatory tissue damage in multiple organs (e.g., lupus nephritis). Current treatments including steroids, antimalarials, and immunosuppressive drugs have significant side effects. There is an unmet medical need for new drugs with less side effects. We evaluated the role of two proteases, namely activated protein C (aPC) and cathepsin S (Cat S), in the pathogenesis of SLE in MRL-Fas(lpr) mice.

Autorentext

I received a M.Sc in Biotechnology from Sri Venkateswara University,Tirupati, AP, India and a PhD in Immunology from Ludwig Maximilians University of Munich, Germany. I joined the Center for Neuroscience, IISc, Bengaluru in June 2013.